The Use of Tissue-Engineered Skin (Apligraf) to Treat a Newborn With Epidermolysis Bullosa

Abstract

Our early success with tissue-engineered skin in this patient may have a significant impact on the future treatment of neonates with EB simplex. Future studies are needed to determine if the beneficial effects of tissue-engineered skin are reproducible in other neonates with EB simplex and in patients of all ages with different subtypes of EB.